Endevica Bio spins off Abisati to develop oral MC4 receptor agonist for weight loss

Nov. 4, 2024

Endevica Bio Inc. has announced the spin-off of a newly created company, Abisati LLC, to develop an oral melanocortin MC4 receptor agonist, 710GO, as a weight loss therapy.

BioWorld Science Endocrine/metabolic Peptide

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 21, 2025.

Coinfections and diversity paint the many shades of HIV cure

BioWorld

We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...

Engineered IL-18 variants with improved drug-like properties show promise for cancer immunotherapy

BioWorld Science

Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in promoting antitumor immunity by activating T and natural killer (NK) cells....

In ongoing mRNA evolution, SML Biopharm sights new cancer vaccines

BioWorld

SML Biopharm Co. Ltd. is harnessing mRNA technology to develop novel immunotherapy-based cancer vaccines, including two candidates for cervical and head and neck...